WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and dicer substrate RNA (DsiRNA) molecules, today announced the appointment of pharmaceutical industry veteran David M. Madden as Dicerna’s independent chairman of the Board. The appointment was confirmed during the Company’s most recent Board of Directors meeting and is effective immediately. Douglas M. Fambrough, Ph.D., general partner with Oxford Biosciences Partners, and previous chairman, remains on the now six-person Dicerna Board.
